Alembic Pharma Gets USFDA Tentative Nod For Alcaftadine Ophthalmic Solution Kumar Jeetendra | April 21, 2020 Alembic Pharmaceuticals Limited has reported that it has gotten provisional endorsement from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Alcaftadine Ophthalmic Solution, 0.25%. The endorsed ANDA is remedially equal to the reference recorded medication item (RLD) Lastacaft Ophthalmic Solution, 0.25%, of Allergan, Inc. (Allergan). Alcaftadine Ophthalmic Solution is …
More than 13 million kids didn’t get any antibodies whatsoever even before COVID-19 disturbed worldwide vaccination-UNICEF Kumar Jeetendra | April 25, 2020 As the world stands by urgently for an antibody, the COVID-19 pandemic is proceeding to flood over the globe. A large number of youngsters are at risk for missing life-sparing antibodies against measles, diphtheria and polio because of interruptions in vaccination administrations. Last time anyone checked, most nations had suspended mass polio battles and 25 …
Untargeted metabolomics can decide hereditary variation to improve understanding finding Kumar Jeetendra | July 8, 2020 A family and patient walk into a physician’s office. They expect that the most recent tests will show what’s causing the individual’s disease and finish the diagnostic odyssey they’ve been going through for ages. Possessing a precise identification also suggests that perhaps there’s a remedy that can relieve the individual’s condition. To identify the genetic …
Rising hydrogel material could improve oral drug delivery Kumar Jeetendra | July 17, 2020 A emerging hydrogel material with the capability to degrade and reform from the gastro intestinal tract can help scientists develop effective procedures for oral drug delivery. The team’s microrheology research is included within a guide and interior cover example from the present dilemma of Soft Issue . To describe the material and supply insight to …
CARE consortium dispatches to quicken drug discovery and improvement for COVID-19 Kumar Jeetendra | August 19, 2020 Using a grant approximately $77.7 million, CARE is funded by cash donations by the European Union (EU) and money and in-kind contributions from Australian European Federation of Pharmaceutical Industries and Associations (EFPIA) businesses and three IMI-Associated Partners. CARE is a five-year project bringing together 37 partners from Belgium, China, Denmark, France, Germany, the Netherlands, Poland, …
New polygenic danger score to help foresee the chances of medications causing liver harm Kumar Jeetendra | September 20, 2020 The ancient Romans studied the livers of sacrificial animals to read omens and create prophesies. Researchers at Tokyo Medical and Dental University (TMDU) and Takeda-CiRA program alongside a world-wide group of collaborators, have devised a polygenic risk score (PRS) based on liver genomics that can predict the probability of medications causing liver damage. Adding new …
New initiative identifies key parameters Inherent effective anti-tumor immunity Kumar Jeetendra | October 10, 2020 Neoantigens, tiny markers that arise from cancer mutations, flag cells as cancerous and could be the key to unlocking a new generation of immunotherapies. Targeting the”right” neoantigens – at a cancer vaccine or a cell treatment – has the promise to eliminate a patient’s cancer with minimal side effects. But countless mutations can exist in …
Trial ALS drug shows potential to drag out patient endurance Kumar Jeetendra | October 18, 2020 An experimental medicine that was recently shown to slow the progression of the neurodegenerative disease amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, has now demonstrated the capacity to also prolong patient survival. The findings come from a clinical trial conducted by investigators at the Sean M. Healey & AMG Center for ALS at Massachusetts …
Polypill in addition to headache medicine and polypill alone reduced cardiovascular sickness hazard Kumar Jeetendra | November 17, 2020 A single, daily pill combining blood pressure and cholesterol medications, as well as the addition of a daily dose of aspirin, reduced cardiovascular disease events in people at risk for heart disease, according to late-breaking study presented today in a late-breaking clinical trial presentation at the American Heart Association’s Scientific Sessions 2020. The virtual conference, …
Dexamethasone use could reduce immune checkpoint inhibitor viability in glioblastoma patients Kumar Jeetendra | November 25, 2020 Bottom Line: One of patients with glioblastoma getting an immune checkpoint inhibitor, people who obtained the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival. Journal Where the Study was Released: Clinical Cancer Research, a journal of the American Association for Cancer Research Author: David A. Reardon, MD, clinical director of the …
FDA favors first conventional glucagon for injection to treat extreme hypoglycemia Kumar Jeetendra | December 29, 2020 Today, the U.S. Food and Drug Administration approved the first generic of glucagon for injection USP, 1 mg/vial packed in an emergency kit, for the treatment of severe hypoglycemia (very low blood sugar), which may occur in patients with diabetes mellitus. The drug is also indicated as a diagnostic aid in the radiologic examination of …
Scientists plan new biosynthetic pathways for short-chain essential amines Kumar Jeetendra | January 18, 2021 Researchers report a new strategy for the microbial production of multiple short-chain primary amines through retrobiosynthesis. KAIST metabolic engineers introduced the bio-based production of numerous short-chain primary amines that have a broad assortment of applications in chemical industries for the first time. The research team led by Distinguished Professor Sang Yup Lee from the Department …
